Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

16.3K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.3K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

9.9K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
9.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.

European journal of nuclear medicine and molecular imaging·2026
Same author

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

The Lancet. Haematology·2026
Same author

Optimizing CAR-T therapy delivery in the Italian healthcare system: economic and organizational insights in follicular lymphoma.

Global & regional health technology assessment·2026
Same author

CD56<sup>+</sup>/CD38<sup>+</sup> Neutrophils: Rapid and Specific Flow Cytometric Signature for Chronic Myeloid Leukemia.

Mediterranean journal of hematology and infectious diseases·2026
Same author

Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.

Blood advances·2026
Same author

Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial.

HemaSphere·2026

Related Experiment Video

Updated: Mar 6, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K

Primary mediastinal large B-cell lymphoma.

Maurizio Martelli1, Andrés Ferreri2, Alice Di Rocco1

  • 1Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

Critical Reviews in Oncology/Hematology
|March 21, 2017
PubMed
Summary
This summary is machine-generated.

Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct lymphoma subtype. Current treatments show good survival, but advanced therapies like DA-EPOCH-R warrant further investigation for optimal outcomes.

Keywords:
ChemotherapyConsolidation radiotherapyHistopathologyImmunotherapyPET-CT scanPrimary mediastinal large B-cell lymphomaPrognostic factors

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

908
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.5K

Related Experiment Videos

Last Updated: Mar 6, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

908
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.5K

Area of Science:

  • Oncology
  • Hematology
  • Immunology

Background:

  • Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct subtype of diffuse large B-cell lymphoma (DLBCL).
  • PMLBCL predominantly affects young females and accounts for 6%-10% of all DLBCL cases.
  • This lymphoma is characterized by a diffuse proliferation of medium to large B-cells and associated sclerosis, with distinct molecular features.

Purpose of the Study:

  • To review the distinct characteristics of PMLBCL compared to other DLBCL subtypes.
  • To evaluate the efficacy of current and emerging treatment strategies for PMLBCL.
  • To assess the role of mediastinal radiotherapy and PET-CT in PMLBCL management.

Main Methods:

  • Review of existing literature on PMLBCL diagnosis, treatment, and outcomes.
  • Analysis of data from clinical trials investigating Rituximab-based regimens (CHOP/MACOP-B-like) with or without mediastinal radiotherapy (RT).
  • Evaluation of studies exploring intensive regimens such as DA-EPOCH-R and the utility of PET-CT scans for response assessment.

Main Results:

  • Rituximab-based regimens combined with mediastinal RT achieve a 5-year progression-free survival (PFS) of 75%-85%.
  • Intensive regimens like DA-EPOCH-R without mediastinal RT show promising results, though require further validation.
  • PET-CT is a valuable tool for assessing treatment response, potentially guiding de-escalation of RT.

Conclusions:

  • PMLBCL is a unique entity requiring specific treatment considerations.
  • While established regimens offer good outcomes, intensive therapies like DA-EPOCH-R present a promising therapeutic advance.
  • Further prospective studies are needed to confirm the efficacy of new regimens and to precisely define the role of mediastinal RT and PET-CT in PMLBCL treatment de-escalation.